SOP Guide for Pharma

BA-BE Studies: SOP for Responding to Ethics Committee Queries – V 2.0

BA-BE Studies: SOP for Responding to Ethics Committee Queries – V 2.0

Standard Operating Procedure for Responding to Ethics Committee Queries in BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/017/2025
Supersedes SOP/BA-BE/017/2022
Page No. Page 1 of 12
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To define a systematic and compliant process for addressing Ethics Committee (EC) or Institutional Review Board (IRB) queries related to Bioavailability/Bioequivalence (BA/BE) studies to ensure timely resolution, protocol integrity, and ethical compliance.

2. Scope

This SOP applies to all BA/BE studies involving EC/IRB submissions, including initial reviews, amendments, and continuing reviews across global and

Indian clinical research centers.

3. Responsibilities

  • Regulatory Affairs: Coordinates response preparation and ensures all communications are aligned with regulatory standards.
  • Clinical Study Team: Provides data, documents, or clarifications needed for EC query resolution.
  • Medical Writer: Drafts written responses or updates to protocols/ICFs as applicable.
  • Principal Investigator (PI): Reviews and signs response packages before submission.

4. Accountability

The Head of Clinical Operations is accountable for ensuring that all EC queries are responded to within stipulated timelines and tracked for regulatory and audit readiness.

5. Procedure

5.1 Query Receipt and Acknowledgment

  1. Receive query communication from the EC via email, portal, or physical letter.
  2. Enter query details in Annexure-1: Ethics Committee Query Log.
  3. Acknowledge receipt within 1–2 working days to the EC (if acknowledgment requested).

5.2 Query Review and Assignment

  1. Assign responsible personnel for each query category:
    • Protocol-related – Medical Affairs / Clinical Team
    • Informed Consent – Medical Writer / Legal
    • Site Documentation – Regulatory / PI
  2. Discuss complex queries in a cross-functional meeting.

5.3 Response Preparation

  1. Draft responses in clear, concise, and scientifically valid language.
  2. Include supporting documentation (highlighted and version-controlled).
  3. Maintain version history in Annexure-2: Query Response Compilation Sheet.

5.4 Review and Approval

  1. Clinical team and Regulatory Affairs review the final response package.
  2. PI to review and sign cover letter or relevant forms.

5.5 Submission to Ethics Committee

  1. Submit via EC’s preferred method (physical, email, portal).
  2. Track submission status in Annexure-3: EC Response Submission Tracker.

5.6 Post-Submission Documentation

  1. File all queries, responses, and approvals in the electronic Trial Master File (eTMF).
  2. Document EC feedback, conditional approvals, or further clarifications.

6. Abbreviations

  • EC: Ethics Committee
  • IRB: Institutional Review Board
  • PI: Principal Investigator
  • eTMF: Electronic Trial Master File
  • SOP: Standard Operating Procedure

7. Documents

  1. Ethics Committee Query Log – Annexure-1
  2. Query Response Compilation Sheet – Annexure-2
  3. EC Response Submission Tracker – Annexure-3

8. References

  • ICH E6(R2) – Good Clinical Practice
  • Schedule Y – Drugs and Cosmetics Rules, India
  • WHO GCP Guidelines

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Ethics Committee Query Log

Date Received EC Name Study Code Query Summary Assigned To
12/04/2025 Institutional EC – Delhi BE-027 Clarify sample size calculation Dr. Ramesh Sinha

Annexure-2: Query Response Compilation Sheet

Query No. Query Response Version Date
1 ICF lacks SAE reporting details Added SAE clause in Section 6 V2.0 13/04/2025

Annexure-3: EC Response Submission Tracker

Submission Date Study Code Method Status Remarks
15/04/2025 BE-027 Email Under EC Review Submitted with revised ICF

Revision History:

Revision Date Revision No. Details Reason Approved By
15/01/2022 1.0 Initial release New SOP QA Head
17/04/2025 2.0 Added annexures, clarified cross-functional responsibilities Process Improvement QA Head
Exit mobile version